Efficacy of Qianlie Shutong Capsule in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Single-Centre Retrospective Study
Abstract
BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent urological condition affecting men's health. This study aims to investigate the clinical efficacy of Qianlie Shutong (QLST) capsule in the treatment of CP/CPPS.
METHODS: The medical records of patients with CP/CPPS who were admitted to our hospital from January 2023 to January 2024 were retrospectively analysed. They were divided into observation and control groups according to treatment modality received. The control group received levofloxacin (0.5 g, qd) in combination with tamsulosin hydrochloride (0.2 mg, qd). The observation group received an additional supplementation of QLST capsule (0.4 g, tid) alongside the treatment administered to the control group. Both groups underwent treatment for 28 days. Baseline data and clinical outcomes were compared between the groups, including the National Institute of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), maximum urine flow rate (Qmax), urine volume (UV), prostate-specific extracellular vesicle protein (PSEP) and International Index of Erectile Function-15 (IIEF-15).
RESULTS: A total of 117 patients were enrolled in this study, comprising 60 in the observation group and 57 in the control group. No significant differences in baseline characteristics were found between the two groups (p > 0.05). Before intervention, no significant differences in NIH-CPSI, Qmax, UV, PSEP and IIEF-15 were found between the two groups (p > 0.05). Following…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 117 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.